Potter exits Genentech after medical problems

Share this article:
Genentech's Myrtle Potter has stepped down from her post as president of commercial operations following a series of medical problems. She will continue to serve as a consultant to the company, Genentech said.
Potter will be succeeded by Ian Clark, senior vice president and general manager of BioOncology who has been running commercial operations in an acting role for the past eight months.
Potter joined Genentech in 2000 as executive vice president and chief operating officer and has overseen the successful launch of six new products including, Avastin, Raptiva, Xolair, Nutropin AQ Pen, Cathflo Activase, and TNKase. In March 2004 she was promoted to president of commercial operations.
Potter had been on leave since late December, a fact the company had not formally disclosed until this week.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.